EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Pharmacological targeting of the mycothiol cysteine ligase MshC in Mycobacterium abscessus

Thanh Quang Nguyen, Claire Hamela, Luping Pang, Yi Liu, Greta Carola Giannini, Lucas Boeck, Gerald Larrouy-Maumus, Laurent Kremer

Journal of Biological Chemistry · 2026

DOI: 10.1016/j.jbc.2026.111433 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2026. Verfasst von Thanh Quang Nguyen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Centre National de la Recherche Scientifique UMR 9004, Institut de Recherche en Infectiologie de Montpellier (IRIM), Université de Montpellier, Montp…. Hauptthemen laut MEDLINE: Mycobacterium abscessus, Inositol, Cysteine, Glycopeptides. Die Arbeit nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Agence Nationale de la Recherche, UK Research and Innovation Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The prevalence of pulmonary diseases caused by Mycobacterium abscessus is on the rise and surpasses tuberculosis in many countries. However, intrinsic resistance of this pathogen to antibiotics profoundly limits our therapeutic arsenal, and new chemotherapeutic agents and targets are urgently needed. Mycothiol (MSH), the major thiol in mycobacteria, plays an important role in resistance to oxidative stress. Previous work in Mycobacterium smegmatis and Mycobacterium tuberculosis indicates that the ATP-dependent cysteine ligase MshC catalyzes the penultimate step in MSH biogenesis. Here, we investigated whether MshC represents a potent drug target in M. abscessus. CRISPRi was used to demonstrate that mshC is essential in vitro and during infection in zebrafish larvae. Subsequently, in silico drug screening identified three potential MshC-binding molecules, namely rebastinib, olverembatinib and SB-224289, significantly inhibiting M. abscessus growth and MSH production. Spontaneous missense mutations in MshC generated cross-resistance to all three compounds. Mapping the mutations conferring resistance on a MshC three-dimensional homology model defined the enzyme catalytic site as the potential drug binding cavity. Additionally, overexpression of mshC in a susceptible M. abscessus strain increased resistance levels to rebastinib, olverembatinib and SB-224289, but not to rifabutin. Conversely, reduced mshC expression levels in the CRISPRi mutant increased susceptibility to the inhibitors. Systematic assessment of olverembatinib and SB-224289 in combination with 18 additional drugs revealed distinct synergistic and antagonistic interactions. These results emphasize a yet unexploited chemical structure class against M. abscessus and highlight the potential of targeting the MSH pathway for future translational developments against M. abscessus lung diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium abscessusInositolCysteineGlycopeptidesAnti-Bacterial AgentsLigasesEnzyme InhibitorsAnimalsZebrafishMicrobial Sensitivity Tests

Stichwörter der Autor:innen

CRISPRiMshCMycobacterium abscessusantibiotic resistancedrug screeninginhibitionmycothiol

Substanzen

mycothiolInositolCysteineGlycopeptidesAnti-Bacterial AgentsLigasesEnzyme Inhibitors

Autor:innen und Institutionen

  • Centre National de la Recherche Scientifique UMR 9004, Institut de Recherche en Infectiologie de Montpellier (IRIM), Université de Montpellier, Montpellier, France.
  • Department of Medical Genetics and Cell Biology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.
  • Faculty of Natural Sciences, Department of Life Sciences, Centre for Bacterial Resistance Biology, Imperial College London, London, United Kingdom.
  • Department of Biomedicine, University of Basel, Basel, Switzerland.
  • Centre National de la Recherche Scientifique UMR 9004, Institut de Recherche en Infectiologie de Montpellier (IRIM), Université de Montpellier, Montpellier, France; INSERM, IRIM, Montpellier, France. Electronic address:…

Förderung

  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
  • Agence Nationale de la Recherche
  • UK Research and Innovation Medical Research Council
  • Foundation for Medical Research

Zitieren

APA

Nguyen, T. Q., Hamela, C., Pang, L., Liu, Y., Giannini, G. C., Boeck, L., Larrouy-Maumus, G., & Kremer, L. (2026). Pharmacological targeting of the mycothiol cysteine ligase MshC in Mycobacterium abscessus. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2026.111433

Vancouver

Nguyen TQ, Hamela C, Pang L, Liu Y, Giannini GC, Boeck L, et al. Pharmacological targeting of the mycothiol cysteine ligase MshC in Mycobacterium abscessus. Journal of Biological Chemistry. 2026. doi:10.1016/j.jbc.2026.111433

BibTeX
@article{Nguyen2026,
  author = {Nguyen, Thanh Quang and Hamela, Claire and Pang, Luping and Liu, Yi and Giannini, Greta Carola and Boeck, Lucas and Larrouy-Maumus, Gerald and Kremer, Laurent},
  title = {Pharmacological targeting of the mycothiol cysteine ligase MshC in Mycobacterium abscessus},
  journal = {Journal of Biological Chemistry},
  year = {2026},
  doi = {10.1016/j.jbc.2026.111433}
}
Kostenlos starten →